Skip to main content
Top
Published in: International Urology and Nephrology 8/2015

01-08-2015 | Urology - Original Paper

Is histological prostate inflammation in an initial prostate biopsy a predictor of prostate cancer on repeat biopsy?

Authors: Bu Hyeon Yun, Eu Chang Hwang, Ho Song Yu, Hoseok Chung, Sun-Ouck Kim, Seung Il Jung, Taek won Kang, Dong Deuk Kwon, Kwangsung Park, Chan Choi

Published in: International Urology and Nephrology | Issue 8/2015

Login to get access

Abstract

Purpose

To investigate whether histological inflammation detected in an initial prostate biopsy can predict the risk of prostate cancer on a repeat biopsy.

Methods

This was a retrospective study of 171 patients who underwent repeat prostate biopsy for persistently elevated prostate-specific antigen after an initial negative biopsy result. The enrolled patients were divided into two groups according to the results of the repeat biopsy: the noncancer group (n = 126) and the cancer group (n = 45). Multivariate regression analysis was used to determine the effect of inflammation grade, aggressiveness, and prostate-related parameters on the detection of prostate cancer at the repeat biopsy.

Results

Prostate inflammation grade (p = 0.005) and aggressiveness (p = 0.001) in the initial biopsy were significantly different between the cancer and noncancer groups. Factors associated with the risk of prostate cancer at the repeat biopsy were age [odds ratio (OR) 1.08; 95 % confidence interval (CI) 1.03–1.14], prostate-specific antigen density (OR 24.30; 95 % CI 9.3–62.9), prostate-specific antigen velocity (OR 1.05; 95 % CI 1.01–1.09), and inflammation aggressiveness (OR 0.05; 95 % CI 0.01–0.27).

Conclusions

A histological inflammatory finding at the initial prostate biopsy was negatively associated with prostate cancer detection in repeat biopsy. This result could be useful to determine the need for repeat prostate biopsy in patients with persistently elevated prostate-specific antigen.
Literature
1.
go back to reference Roberts RO, Bergstralh EJ, Lieber MM, Jacobsen SJ (2000) Digital rectal examination and prostate-specific antigen abnormalities at the time of prostate biopsy and biopsy outcomes, 1980 to 1997. Urology 56:817–822PubMedCrossRef Roberts RO, Bergstralh EJ, Lieber MM, Jacobsen SJ (2000) Digital rectal examination and prostate-specific antigen abnormalities at the time of prostate biopsy and biopsy outcomes, 1980 to 1997. Urology 56:817–822PubMedCrossRef
2.
go back to reference Littrup PJ, Bailey SE (2000) Prostate cancer: the role of transrectal ultrasound and its impact on cancer detection and management. Radiol Clin N Am 38:87–113PubMedCrossRef Littrup PJ, Bailey SE (2000) Prostate cancer: the role of transrectal ultrasound and its impact on cancer detection and management. Radiol Clin N Am 38:87–113PubMedCrossRef
3.
go back to reference Roehl KA, Antenor JA, Catalona WJ (2002) Serial biopsy results in prostate cancer screening study. J Urol 167:2435–2439PubMedCrossRef Roehl KA, Antenor JA, Catalona WJ (2002) Serial biopsy results in prostate cancer screening study. J Urol 167:2435–2439PubMedCrossRef
4.
go back to reference Nam RK, Saskin R, Lee Y et al (2010) Increasing hospital admission rates for urological complications after transrectal ultrasound guided prostate biopsy. J Urol 183:963–968PubMedCrossRef Nam RK, Saskin R, Lee Y et al (2010) Increasing hospital admission rates for urological complications after transrectal ultrasound guided prostate biopsy. J Urol 183:963–968PubMedCrossRef
5.
go back to reference Partin AW, Carter HB, Chan DW et al (1990) Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia. J Urol 143:747–752PubMed Partin AW, Carter HB, Chan DW et al (1990) Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia. J Urol 143:747–752PubMed
6.
go back to reference Nadler RB, Humphrey PA, Smith DS, Catalona WJ, Ratliff TL (1995) Effect of inflammation and benign prostatic hyperplasia on elevated serum prostate specific antigen levels. J Urol 154:407–413PubMedCrossRef Nadler RB, Humphrey PA, Smith DS, Catalona WJ, Ratliff TL (1995) Effect of inflammation and benign prostatic hyperplasia on elevated serum prostate specific antigen levels. J Urol 154:407–413PubMedCrossRef
7.
go back to reference Cohen RJ, Shannon BA, McNeal JE, Shannon T, Garrett KL (2005) Propionibacterium acnes associated with inflammation in radical prostatectomy specimens: a possible link to cancer evolution? J Urol 173:1969–1974PubMedCrossRef Cohen RJ, Shannon BA, McNeal JE, Shannon T, Garrett KL (2005) Propionibacterium acnes associated with inflammation in radical prostatectomy specimens: a possible link to cancer evolution? J Urol 173:1969–1974PubMedCrossRef
8.
go back to reference Nickel JC, True LD, Krieger JN, Berger RE, Boag AH, Young ID (2001) Consensus development of a histopathological classification system for chronic prostatic inflammation. BJU Int 87:797–805PubMedCrossRef Nickel JC, True LD, Krieger JN, Berger RE, Boag AH, Young ID (2001) Consensus development of a histopathological classification system for chronic prostatic inflammation. BJU Int 87:797–805PubMedCrossRef
9.
go back to reference Irani J, Levillain P, Goujon JM, Bon D, Doré B, Aubert J (1997) Inflammation in benign prostatic hyperplasia: correlation with prostate specific antigen value. J Urol 157:1301–1303PubMedCrossRef Irani J, Levillain P, Goujon JM, Bon D, Doré B, Aubert J (1997) Inflammation in benign prostatic hyperplasia: correlation with prostate specific antigen value. J Urol 157:1301–1303PubMedCrossRef
10.
go back to reference Fleshner NE, O’Sullivan M, Fair WR (1997) Prevalence and predictors of a positive repeat transrectal ultrasound guided needle biopsy of the prostate. J Urol 158:505–508PubMedCrossRef Fleshner NE, O’Sullivan M, Fair WR (1997) Prevalence and predictors of a positive repeat transrectal ultrasound guided needle biopsy of the prostate. J Urol 158:505–508PubMedCrossRef
11.
go back to reference Noguchi M, Yahara J, Koga H, Nakashima O, Noda S (1999) Necessity of repeat biopsies in men for suspected prostate cancer. Int J Urol 6:7–12PubMedCrossRef Noguchi M, Yahara J, Koga H, Nakashima O, Noda S (1999) Necessity of repeat biopsies in men for suspected prostate cancer. Int J Urol 6:7–12PubMedCrossRef
12.
go back to reference Durkan GC, Greene DR (1999) Elevated serum prostate specific antigen levels in conjunction with an initial prostatic biopsy negative for carcinoma: who should undergo a repeat biopsy? BJU Int 83:34–38PubMedCrossRef Durkan GC, Greene DR (1999) Elevated serum prostate specific antigen levels in conjunction with an initial prostatic biopsy negative for carcinoma: who should undergo a repeat biopsy? BJU Int 83:34–38PubMedCrossRef
13.
go back to reference Merrimen JL, Jones G, Walker D, Leung CS, Kapusta LR, Srigley JR (2009) Multifocal high grade prostatic intraepithelial neoplasia is a significant risk factor for prostatic adenocarcinoma. J Urol 182:485–490PubMedCrossRef Merrimen JL, Jones G, Walker D, Leung CS, Kapusta LR, Srigley JR (2009) Multifocal high grade prostatic intraepithelial neoplasia is a significant risk factor for prostatic adenocarcinoma. J Urol 182:485–490PubMedCrossRef
14.
go back to reference Lee JG, Bae SH, Choi SH, Kwon TG, Kim TH (2012) Role of prostate-specific antigen change ratio at initial biopsy as a novel decision-making marker for repeat prostate biopsy. Korean J Urol 53:467–471PubMedCentralPubMedCrossRef Lee JG, Bae SH, Choi SH, Kwon TG, Kim TH (2012) Role of prostate-specific antigen change ratio at initial biopsy as a novel decision-making marker for repeat prostate biopsy. Korean J Urol 53:467–471PubMedCentralPubMedCrossRef
15.
go back to reference Catalona WJ, Partin AW, Slawin KM et al (1998) Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA 279:1542–1547PubMedCrossRef Catalona WJ, Partin AW, Slawin KM et al (1998) Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA 279:1542–1547PubMedCrossRef
16.
go back to reference Morgan TO, McLeod DG, Leifer ES, Murphy GP, Moul JW (1996) Prospective use of free prostate-specific antigen to avoid repeat prostate biopsies in men with elevated total prostate-specific antigen. Urology 48:76–80PubMedCrossRef Morgan TO, McLeod DG, Leifer ES, Murphy GP, Moul JW (1996) Prospective use of free prostate-specific antigen to avoid repeat prostate biopsies in men with elevated total prostate-specific antigen. Urology 48:76–80PubMedCrossRef
17.
go back to reference Vignozzi L, Maggi M (2014) Prostate cancer: intriguing data on inflammation and prostate cancer. Nat Rev Urol 11:369–370PubMedCrossRef Vignozzi L, Maggi M (2014) Prostate cancer: intriguing data on inflammation and prostate cancer. Nat Rev Urol 11:369–370PubMedCrossRef
18.
go back to reference Corona G, Vignozzi L, Rastrelli G, Lotti F, Cipriani S, Maggi M (2014) Benign prostatic hyperplasia: a new metabolic disease of the aging male and its correlation with sexual dysfunctions. Int J Endocrinol 2014:329456PubMedCentralPubMed Corona G, Vignozzi L, Rastrelli G, Lotti F, Cipriani S, Maggi M (2014) Benign prostatic hyperplasia: a new metabolic disease of the aging male and its correlation with sexual dysfunctions. Int J Endocrinol 2014:329456PubMedCentralPubMed
19.
go back to reference Brawer MK, Rennels MA, Nagle RB, Schifman R, Gaines JA (1989) Serum prostate-specific antigen and prostate pathology in men having simple prostatectomy. Am J Clin Pathol 92:760–764PubMed Brawer MK, Rennels MA, Nagle RB, Schifman R, Gaines JA (1989) Serum prostate-specific antigen and prostate pathology in men having simple prostatectomy. Am J Clin Pathol 92:760–764PubMed
20.
go back to reference Schatteman PH, Hoekx L, Wyndaele JJ, Jeuris W, Van Marck E (2000) Inflammation in prostate biopsies of men without prostatic malignancy or clinical prostatitis: correlation with total serum PSA and PSA density. Eur Urol 37:404–412PubMedCrossRef Schatteman PH, Hoekx L, Wyndaele JJ, Jeuris W, Van Marck E (2000) Inflammation in prostate biopsies of men without prostatic malignancy or clinical prostatitis: correlation with total serum PSA and PSA density. Eur Urol 37:404–412PubMedCrossRef
21.
go back to reference Kandirali E, Boran C, Serin E, Semercioz A, Metin A (2007) Association of extent and aggressiveness of inflammation with serum PSA levels and PSA density in asymptomatic patients. Urology 70:743–747PubMedCrossRef Kandirali E, Boran C, Serin E, Semercioz A, Metin A (2007) Association of extent and aggressiveness of inflammation with serum PSA levels and PSA density in asymptomatic patients. Urology 70:743–747PubMedCrossRef
22.
go back to reference Kim HW, Kim SH, Kim SW, Jung KI, Min KO, Cho SY (2009) Effects of subclinical prostatitis on benign prostatic hyperplasia. Korean J Urol 50:154–158CrossRef Kim HW, Kim SH, Kim SW, Jung KI, Min KO, Cho SY (2009) Effects of subclinical prostatitis on benign prostatic hyperplasia. Korean J Urol 50:154–158CrossRef
23.
go back to reference Park CH, Kim SJ, Park CM, Kim HK, Park JY (2009) The influence of prostate chronic inflammation on parameters related to prostate cancer in asymptomatic patients. Korean J Urol Oncol 7:74–81 Park CH, Kim SJ, Park CM, Kim HK, Park JY (2009) The influence of prostate chronic inflammation on parameters related to prostate cancer in asymptomatic patients. Korean J Urol Oncol 7:74–81
24.
go back to reference Terakawa T, Miyake H, Kanomata N, Kumano M, Takenaka A, Fujisawao M (2008) Inverse association between histologic inflammation in needle biopsy specimens and prostate cancer in men with serum PSA of 10–50 ng/mL. Urology 72:1194–1197PubMedCrossRef Terakawa T, Miyake H, Kanomata N, Kumano M, Takenaka A, Fujisawao M (2008) Inverse association between histologic inflammation in needle biopsy specimens and prostate cancer in men with serum PSA of 10–50 ng/mL. Urology 72:1194–1197PubMedCrossRef
25.
go back to reference Pepe P, Aragona F (2011) Does an inflammatory pattern at primary biopsy suggest a lower risk for prostate cancer at repeated saturation prostate biopsy? Urol Int 87:171–174PubMedCrossRef Pepe P, Aragona F (2011) Does an inflammatory pattern at primary biopsy suggest a lower risk for prostate cancer at repeated saturation prostate biopsy? Urol Int 87:171–174PubMedCrossRef
26.
go back to reference Gurel B, Lucia MS, Thompson IM Jr et al (2014) Chronic inflammation in benign prostate tissue is associated with high-grade prostate cancer in the placebo arm of the prostate cancer prevention trial. Cancer Epidemiol Biomark Prev 23:847–856CrossRef Gurel B, Lucia MS, Thompson IM Jr et al (2014) Chronic inflammation in benign prostate tissue is associated with high-grade prostate cancer in the placebo arm of the prostate cancer prevention trial. Cancer Epidemiol Biomark Prev 23:847–856CrossRef
27.
go back to reference Fujita K, Hosomi M, Tanigawa G, Okumi M, Fushimi H, Yamaguchi S (2011) Prostatic inflammation detected in initial biopsy specimens and urinary pyuria are predictors of negative repeat prostate biopsy. J Urol 185:1722–1727PubMedCrossRef Fujita K, Hosomi M, Tanigawa G, Okumi M, Fushimi H, Yamaguchi S (2011) Prostatic inflammation detected in initial biopsy specimens and urinary pyuria are predictors of negative repeat prostate biopsy. J Urol 185:1722–1727PubMedCrossRef
28.
go back to reference Moreira DM, Nickel JC, Gerber L et al (2014) Baseline prostate inflammation is associated with a reduced risk of prostate cancer in men undergoing repeat prostate biopsy: results from the REDUCE study. Cancer 120:190–196PubMedCrossRef Moreira DM, Nickel JC, Gerber L et al (2014) Baseline prostate inflammation is associated with a reduced risk of prostate cancer in men undergoing repeat prostate biopsy: results from the REDUCE study. Cancer 120:190–196PubMedCrossRef
29.
go back to reference Yli-Hemminki TH, Laurila M, Auvinen A et al (2013) Histological inflammation and risk of subsequent prostate cancer among men with initially elevated serum prostate-specific antigen (PSA) concentration in the Finnish prostate cancer screening trial. BJU Int 112:735–741PubMedCrossRef Yli-Hemminki TH, Laurila M, Auvinen A et al (2013) Histological inflammation and risk of subsequent prostate cancer among men with initially elevated serum prostate-specific antigen (PSA) concentration in the Finnish prostate cancer screening trial. BJU Int 112:735–741PubMedCrossRef
30.
go back to reference Delongchamps NB, de la Roza G, Chandan V et al (2008) Evaluation of prostatitis in autopsied prostates-is chronic inflammation more associated with benign prostatic hyperplasia or cancer? J Urol 179:1736–1740PubMedCentralPubMedCrossRef Delongchamps NB, de la Roza G, Chandan V et al (2008) Evaluation of prostatitis in autopsied prostates-is chronic inflammation more associated with benign prostatic hyperplasia or cancer? J Urol 179:1736–1740PubMedCentralPubMedCrossRef
Metadata
Title
Is histological prostate inflammation in an initial prostate biopsy a predictor of prostate cancer on repeat biopsy?
Authors
Bu Hyeon Yun
Eu Chang Hwang
Ho Song Yu
Hoseok Chung
Sun-Ouck Kim
Seung Il Jung
Taek won Kang
Dong Deuk Kwon
Kwangsung Park
Chan Choi
Publication date
01-08-2015
Publisher
Springer Netherlands
Published in
International Urology and Nephrology / Issue 8/2015
Print ISSN: 0301-1623
Electronic ISSN: 1573-2584
DOI
https://doi.org/10.1007/s11255-015-1029-6

Other articles of this Issue 8/2015

International Urology and Nephrology 8/2015 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.